Cambridge biotech Sarepta tops $11B market cap on gene therapy data
June 19, 2018 at 11:13 AM EDT
Sarepta is one of a handful of companies that is developing a drug for Duchenne using gene therapy, a method of inserting healthy genes into a person’s cells to replace missing or faulty ones.
